Research ExplorerPublicationsDevice Therapy for Rate Control: Pacing, Resynchronisation a...

Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation

Standard

Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. / Lau, Dennis H; Thiyagarajah, Anand; Willems, Stephan; Rostock, Thomas; Linz, Dominik; Stiles, Martin K; Kaye, David; Kalman, Jonathan M; Sanders, Prashanthan.

In: HEART LUNG CIRC, Vol. 26, No. 9, 09.2017, p. 934-940.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Lau, DH, Thiyagarajah, A, Willems, S, Rostock, T, Linz, D, Stiles, MK, Kaye, D, Kalman, JM & Sanders, P 2017, 'Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation', HEART LUNG CIRC, vol. 26, no. 9, pp. 934-940. https://doi.org/10.1016/j.hlc.2017.05.124

APA

Lau, D. H., Thiyagarajah, A., Willems, S., Rostock, T., Linz, D., Stiles, M. K., Kaye, D., Kalman, J. M., & Sanders, P. (2017). Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. HEART LUNG CIRC, 26(9), 934-940. https://doi.org/10.1016/j.hlc.2017.05.124

Vancouver

Lau DH, Thiyagarajah A, Willems S, Rostock T, Linz D, Stiles MK et al. Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. HEART LUNG CIRC. 2017 Sep;26(9):934-940. https://doi.org/10.1016/j.hlc.2017.05.124

Bibtex

@article{a378dc4c56a64486be49d5265fbedaf1,
title = "Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation",
abstract = "Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an {"}ablate and pace{"} approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.",
keywords = "Atrial Fibrillation/physiopathology, Atrioventricular Node/surgery, Cardiac Pacing, Artificial/methods, Cardiac Resynchronization Therapy/methods, Catheter Ablation/methods, Heart Rate/physiology, Humans",
author = "Lau, {Dennis H} and Anand Thiyagarajah and Stephan Willems and Thomas Rostock and Dominik Linz and Stiles, {Martin K} and David Kaye and Kalman, {Jonathan M} and Prashanthan Sanders",
note = "Crown Copyright {\textcopyright} 2017. Published by Elsevier B.V. All rights reserved.",
year = "2017",
month = sep,
doi = "10.1016/j.hlc.2017.05.124",
language = "English",
volume = "26",
pages = "934--940",
journal = "HEART LUNG CIRC",
issn = "1443-9506",
publisher = "Elsevier Limited",
number = "9",

}

RIS

TY - JOUR

T1 - Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation

AU - Lau, Dennis H

AU - Thiyagarajah, Anand

AU - Willems, Stephan

AU - Rostock, Thomas

AU - Linz, Dominik

AU - Stiles, Martin K

AU - Kaye, David

AU - Kalman, Jonathan M

AU - Sanders, Prashanthan

N1 - Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.

PY - 2017/9

Y1 - 2017/9

N2 - Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an "ablate and pace" approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.

AB - Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an "ablate and pace" approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.

KW - Atrial Fibrillation/physiopathology

KW - Atrioventricular Node/surgery

KW - Cardiac Pacing, Artificial/methods

KW - Cardiac Resynchronization Therapy/methods

KW - Catheter Ablation/methods

KW - Heart Rate/physiology

KW - Humans

U2 - 10.1016/j.hlc.2017.05.124

DO - 10.1016/j.hlc.2017.05.124

M3 - SCORING: Review article

C2 - 28687248

VL - 26

SP - 934

EP - 940

JO - HEART LUNG CIRC

JF - HEART LUNG CIRC

SN - 1443-9506

IS - 9

ER -